Contract

Quality Admin

Posted on 9/11/2026

Deadline 9/11/27
IBEX

IBEX

1-10 employees

Biotech company: antibodies and gene therapy

No salary listed

Pittsburgh, PA, USA

In Person

Category
Training (1)
Required Skills
Quality Assurance (QA)

Get referred to IBEX

See people who can refer or advise you

Requirements
  • A high school diploma or GED is required.
  • Dual skill in both mobile technology and technology is preferred.
  • An exceptional performance history in quality performance is required.
  • Coaching experience is preferred.
  • Previous quality assessment experience is preferred.
  • Knowledge of adult learning techniques is preferred.
  • Understanding of inbound and outbound operations is desired.
  • Familiarity with fundamental feedback and coaching skills is desired.
  • Prior knowledge of program strategy is strongly desired.
  • Written warnings within the last six months may be reviewed on a case-by-case basis.
  • Drug screening and a background check are required.
Responsibilities
  • Evaluate a random sampling of technical support calls and other customer contact methods for compliance with prescribed client project standards, including adherence to standards, accuracy, customer experience, and contact handling efficiency.
  • Provide one-on-one feedback to advisors.
  • Interface with peers and team managers on best practices and advisor evaluations.
  • Participate in client and management meetings and conference calls.
Desired Qualifications
  • Dual skill in both mobile technology and technology.
  • Coaching experience.
  • Previous quality assessment experience.
  • Knowledge of adult learning techniques.
  • Understanding of inbound and outbound operations.
  • Familiarity with fundamental feedback and coaching skills.
  • Prior knowledge of program strategy.

Ibex Biosciences focuses on discovering, validating, and producing biotechnology solutions for health and ecological challenges. Its product portfolio includes therapeutic antibodies, gene therapy, and stem cell programs, as well as diagnostic antibodies for Immunohistochemistry (IHC) to improve biopsy accuracy. The company advances its products by conducting exploratory R&D on projects that may not yet be validated in public research, then develops and commercializes these technologies through licensing, partnerships, and direct sales to healthcare and research institutions. A key differentiator is Ibex’s diversified, internally driven pipeline and its mix of therapeutics and diagnostics, alongside active engagement in grant funding and patenting. The company’s goal is to bring proprietary biotech innovations to market to enhance patient outcomes and health-related research, addressing significant cancer-related and other health challenges.

Company Size

1-10

Company Stage

Early VC

Total Funding

$4.2M

Headquarters

Rockville, Maryland

Founded

2015

Get referred to IBEX

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 6, 2026 revenue hit $164.4 million, up 16.8% year over year.
  • Management raised FY2026 guidance again on May 6, 2026, signaling sustained demand.
  • May 13, 2026 authorized a $20 million buyback, reinforcing cash generation and confidence.

What critics are saying

  • Telecommunications revenue fell 23.1% in Q3 FY2026; legacy contracts are shrinking.
  • Largest client drove 10% of revenue in Q3 FY2026; one churn hurts margins immediately.
  • GenAI contact-center rivals and client insourcing threaten ibex’s BPO volumes by 2027.

What makes IBEX unique

  • IBEX Limited pairs human agents with Wave iX AI across 2026 deployments.
  • March 31, 2026 filings show 98%+ revenue retention and diversified vertical exposure.
  • Offshore delivery supplied 51% of revenue in Q2 FY2026, lowering labor costs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Ibex Innovations
Mar 12th, 2025
IBEX Completes £2m Fundraise for Osteoporosis

IBEX has successfully completed a £2 million funding round to advance its mission of using X-ray technology to diagnose osteoporosis early. The company aims to shift from reactive to proactive treatment of this silent disease. With partnerships established with X-ray and mammography OEMs in 2024, IBEX plans to deploy its technology in clinical settings by 2025, demonstrating cost savings for the NHS.

Globes
Feb 8th, 2022
Gauzy acquires Vision Systems

Israeli light control nanotech and smart glass company Gauzy has announced that it has acquired French company Vision Systems, which develops ADAS (Advanced Driver Assistance System) and shading solutions for the aeronautic, land transport, and marine industries.